NCT07410117 (ROXI-CAT-I) is a Phase 3 clinical trial of REGN7508 in Cancer-Associated Thrombosis (CAT), sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT07410117?

NCT07410117 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT07410117?

Interventions in NCT07410117: REGN7508, Placebo.

What condition does NCT07410117 study?

NCT07410117 studies Cancer-Associated Thrombosis (CAT).

Is NCT07410117 still recruiting?

NCT07410117 is currently recruiting now. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07410117: ROXI-CAT-I

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Recruiting now Phase 3 Last updated 9 April 2026

What this trial tests

Phase 3 trial testing REGN7508 in Cancer-Associated Thrombosis (CAT) in 860 participants. Currently enrolling.

Timeline

9 March 2026

Primary endpoint
23 January 2030

6 May 2030

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	860
Start date	9 March 2026
Primary completion	23 January 2030
Estimated completion	6 May 2030
Sites	12 locations across Georgia, United States

Drugs / interventions tested

REGN7508 — full drug profile →
Placebo

Conditions studied

Cancer-Associated Thrombosis (CAT) — all drugs for Cancer-Associated Thrombosis (CAT) →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Cancer-Associated Thrombosis (CAT). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of REGN7508

Trials testing the same drug.

NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
NCT07430956 — Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is · Phase 3 · not yet recruiting
NCT07213778 — REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Particip · Phase 3 · recruiting
NCT07175428 — Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation · Phase 2 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07410117 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07410117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing